13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001791827
Total reported value
$624.4M
$624.4M
39 檔
32.4%
At the close of Q4 2025, Avidity Partners Management LP disclosed equity holdings valued at approximately $624.4M, spread across 39 reported holdings.
In Q4 2025, Avidity Partners Management LP adopted a defensive or profit-taking posture, trimming 19 positions and completely liquidating 15 holdings to manage risk exposure.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | DNTH | Dianthus Therapeutics Inc | Stock-Other | 25.01% | -2.91% | -34.33% | |
| 2 | CGON | Cg Oncology Inc | Stock-Other | 17.64% | -1.75% | -8.01% | |
| 3 | JBIO | Jade Biosciences Inc | Stock-Other | 6.23% | +2.06% | +24.27% | |
| 4 | ORKA | Oruka Therapeutics Inc | Stock-Other | 5.77% | +4.04% | — | |
| 5 | TEVA | Teva Pharmaceutical-sp Adr | Stock-Healthcare | 3.76% | -1.66% | -18.18% | |
| 6 | BSX | Boston Scientific CORP | Stock-Healthcare | 3.15% | -0.21% | -30.31% | |
| 7 | MDT | Medtronic plc | Stock-Healthcare | 2.98% | -0.87% | -43.55% | |
| 8 | CATX | Perspective Therapeutics Inc | Stock-Other | 2.55% | -1.67% | +7.24% | |
| 9 | ALNY | Alnylam Pharmaceuticals Inc | Stock-Healthcare | 2.41% | — | — | |
| 10 | RGEN | Repligen CORP | Stock-Healthcare | 2.38% | -0.16% | +115.88% | |
| 11 | CNTX | Context Therapeutics Inc | Stock-Other | 2.33% | -2.21% | -38.71% | |
| 12 | MCK | Mckesson CORP | Stock-Healthcare | 2.25% | — | +64.14% | |
| 13 | ICLR | ICON Public Limited Company | Stock-Healthcare | 1.74% | -0.36% | EXIT | |
| 14 | A | Agilent Technologies Inc | Stock-Healthcare | 1.63% | — | — | |
| 15 | PFE | Pfizer Inc | Stock-Healthcare | 1.46% | — | -44.43% | |
| 16 | CNC | Centene CORP | Stock-Healthcare | 1.42% | -0.46% | EXIT | |
| 17 | KVUE | Kenvue Inc | Stock-Consumer Staples | 1.16% | -0.35% | EXIT | |
| 18 | DHR | Danaher CORP | Stock-Healthcare | 1.12% | — | -68.92% | |
| 19 | TMO | Thermo Fisher Scientific Inc | Stock-Healthcare | 1.12% | — | -64.55% | |
| 20 | NVO | Novo-nordisk A/s-spons Adr | Stock-Healthcare | 0.99% | — | — | |
| 21 | PHAT | Phathom Pharmaceuticals Inc | Stock-Other | 0.99% | -0.21% | -32.65% | |
| 22 | EHC | Encompass Health CORP | Stock-Healthcare | 0.97% | -0.14% | -24.58% | |
| 23 | CI | THE Cigna Group | Stock-Healthcare | 0.92% | — | -30.12% | |
| 24 | COR | Cencora Inc | Stock-Healthcare | 0.92% | — | -50.53% | |
| 25 | INSM | Insmed Inc | Stock-Healthcare | 0.89% | — | +52.59% | |
| 26 | WAT | Waters CORP | Stock-Healthcare | 0.89% | — | — | |
| 27 | ACAD | Acadia Pharmaceuticals Inc | Stock-Healthcare | 0.82% | -0.06% | EXIT | |
| 28 | GMAB | Genmab A/s -sp Adr | Stock-Other | 0.82% | -0.05% | -62.92% | |
| 29 | NTRA | Natera Inc | Stock-Healthcare | 0.78% | -0.36% | EXIT | |
| 30 | VTLUSD | Immunic Inc | Stock-Other | 0.72% | -1.51% | EXIT | |
| 31 | ACHC | Acadia Healthcare Co Inc | Stock-Other | 0.69% | — | — | |
| 32 | ITGR | Integer Holdings CORP | Stock-Healthcare | 0.67% | — | — | |
| 33 | ELVN | Enliven Therapeutics Inc | Stock-Other | 0.62% | +1.29% | — | |
| 34 | PVLA | Palvella Therapeutics Inc | Stock-Other | 0.58% | -0.06% | — | |
| 35 | HQY | Healthequity Inc | Stock-Healthcare | 0.45% | — | -33.20% | |
| 36 | SCYXEUR | Scynexis Inc | Stock-Other | 0.38% | -0.39% | EXIT | |
| 37 | IQV | Iqvia Holdings Inc | Stock-Healthcare | 0.29% | — | — | |
| 38 | KPTI | Karyopharm Therapeutics Inc | Stock-Other | 0.29% | +0.93% | — | |
| 39 | CORT | Corcept Therapeutics Inc | Stock-Healthcare | 0.22% | -0.24% | EXIT |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | JBIO | Jade Biosciences Inc | +4% | +24.27% | Add |
| 2 | CGON | Cg Oncology Inc | +3% | -8.01% | Trim |
| 3 | ORKA | Oruka Therapeutics Inc | +2.9% | — | Unchanged |
| 4 | RGEN | Repligen CORP | +1.7% | +115.88% | Add |
| 5 | TEVA | Teva Pharmaceutical-sp Adr | +1.4% | -18.18% | Trim |
| 6 | MCK | Mckesson CORP | +1.2% | +64.14% | Add |
| 7 | INSM | Insmed Inc | +0.5% | +52.59% | Add |
| 8 | CNTX | Context Therapeutics Inc | +0.4% | -38.71% | Trim |
| 9 | CATX | Perspective Therapeutics Inc | +0.2% | +7.24% | Add |
| 10 | KVUE | Kenvue Inc | +0.2% | -12.22% | Trim |
| 11 | PHAT | Phathom Pharmaceuticals Inc | +0.2% | -32.65% | Trim |
| 12 | ACAD | Acadia Pharmaceuticals Inc | +0.1% | -25.76% | Trim |
| 13 | KPTI | Karyopharm Therapeutics Inc | +0.1% | — | Unchanged |
| 14 | ELVN | Enliven Therapeutics Inc | 0% | — | Unchanged |
| 15 | HQY | Healthequity Inc | -0.1% | -33.20% | Trim |
| 16 | CI | THE Cigna Group | -0.2% | -30.12% | Trim |
| 17 | SCYXEUR | Scynexis Inc | -0.2% | -37.87% | Trim |
| 18 | VTLUSD | Immunic Inc | -0.2% | — | Unchanged |
| 19 | EHC | Encompass Health CORP | -0.2% | -24.58% | Trim |
| 20 | COR | Cencora Inc | -0.4% | -50.53% | Trim |
| 21 | BSX | Boston Scientific CORP | -0.5% | -30.31% | Trim |
| 22 | PFE | Pfizer Inc | -0.7% | -44.43% | Trim |
| 23 | GMAB | Genmab A/s -sp Adr | -0.9% | -62.92% | Trim |
| 24 | TMO | Thermo Fisher Scientific Inc | -1% | -64.55% | Trim |
| 25 | MDT | Medtronic plc | -1.2% | -43.55% | Trim |
| 26 | DHR | Danaher CORP | -1.4% | -68.92% | Trim |
| 27 | NTRA | Natera Inc | -1.8% | -83.24% | Trim |
| 28 | DNTH | Dianthus Therapeutics Inc | -3.7% | -34.33% | Trim |
| 29 | BMY | Bristol-myers Squibb Co | — | EXIT | Sold out |
| 30 | ALNY | Alnylam Pharmaceuticals Inc | — | NEW | New buy |
| 31 | ✓ | — | EXIT | Sold out | |
| 32 | UNH | Unitedhealth Group Inc | — | EXIT | Sold out |
| 33 | ICLR | ICON Public Limited Company | — | NEW | New buy |
| 34 | ARVN | Arvinas Inc | — | EXIT | Sold out |
| 35 | A | Agilent Technologies Inc | — | NEW | New buy |
| 36 | JNJ | Johnson & Johnson | — | EXIT | Sold out |
| 37 | CNC | Centene CORP | — | NEW | New buy |
| 38 | ABBV | Abbvie Inc | — | EXIT | Sold out |
| 39 | CARL | Carlsmed Inc | — | EXIT | Sold out |
| 40 | ARQT | Arcutis Biotherapeutics Inc | — | EXIT | Sold out |
| 41 | EXK | Exact Sciences CORP | — | EXIT | Sold out |
| 42 | NVO | Novo-nordisk A/s-spons Adr | — | NEW | New buy |
| 43 | WAT | Waters CORP | — | NEW | New buy |
| 44 | ASND | Ascendis Pharma A/S | — | EXIT | Sold out |
| 45 | BEAM | Beam Therapeutics Inc | — | EXIT | Sold out |
| 46 | ACHC | Acadia Healthcare Co Inc | — | NEW | New buy |
| 47 | ITGR | Integer Holdings CORP | — | NEW | New buy |
| 48 | WVE | Wave Life Sciences Ltd. | — | EXIT | Sold out |
| 49 | XENE | Xenon Pharmaceuticals Inc | — | EXIT | Sold out |
| 50 | PVLA | Palvella Therapeutics Inc | — | NEW | New buy |
According to official SEC Form 13F filings, Avidity Partners Management LP reported a total U.S. public equity portfolio value of $624.4M across 39 disclosed positions in Q4 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including DNTH, CGON, JBIO) accounted for 32.4% of total reported equity market value during Q4 2025.
Top New Position Initiated
ALNY
市值: $8.4M
Top Position Liquidated / Trimmed
BMY
前期市值: $11.6M
During Q4 2025, Avidity Partners Management LP's top holdings by market value included DNTH (25.0%)、CGON (17.6%)、JBIO (6.2%). The largest single position, DNTH, represented 25.0% of total portfolio value.
In Q4 2025, Avidity Partners Management LP made 50 total portfolio adjustments, initiating 11 new buys, adding to 5 positions, trimming 19 holdings, and fully liquidating 15 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.